CTOs on the Move

WV Health Information Network

www.wvhin.org

 
The West Virginia Health Information Network (WVHIN) offers services that enable the secure electronic exchange of patient health information, providing benefits to health care providers, health care systems and patients. In February 2010, the West Virginia Department of Health and Human Resources received $7.8 million in federal funds as part of the State Health Information Exchange Cooperative Agreement Program. The West Virginia Health Information Network (WVHIN) is using these funds to launch WVHIN’s statewide electronic health information exchange services. In August 2011, the WVHIN chose Truven Health Analytics as its technical services partner.  Together with Truven Health and its strategic partners, the WVHIN ...
  • Number of Employees: 0-25
  • Annual Revenue: $100-250 Million
  • www.wvhin.org
  • 100 Dee Drive
    Charleston, WV USA 25311
  • Phone: 304.558.4503

Executives

Name Title Contact Details

Similar Companies

Radia

Radia is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nebraska Heart Institute

Nebraska Heart Institute is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Desert Senita Community Health Center

Desert Senita Community Health Center is a Ajo, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

24Hr HomeCare

24Hr HomeCare is a El Segundo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.